Counts Scott E, Ray Balmiki, Mufson Elliott J, Perez Sylvia E, He Bin, Lahiri Debomoy K
Department of Translational Science and Molecular Medicine, Michigan State University, 333 Bostwick Ave NE, Grand Rapids, MI, 49503, USA,
J Clin Immunol. 2014 Jul;34 Suppl 1(0 1):S80-5. doi: 10.1007/s10875-014-0020-9. Epub 2014 Apr 24.
Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.
静脉注射免疫球蛋白（IVIG）在阿尔茨海默病（AD）的人体临床研究中迄今显示出有限的前景，但在动物和人脑培养物中的临床前研究结果绝大多数呈阳性，这支持了该疗法仍具有潜在疗效的观点。在此，我们通过证明IVIG在体外保护人原代神经元免受氧化应激，以及IVIG在体内维持抗氧化防御机制，来详细阐述IVIG的神经保护作用。基于这些结果，我们提出以下转化影响：如果剂量和治疗条件得到充分优化，那么IVIG治疗可能在预防和/或延缓神经退行性疾病（如AD）的进展中发挥重要作用。我们认为IVIG值得进一步研究，以充分挖掘其作为抗氧化、神经保护和突触保护剂的潜力。
